Complete response to neoadjuvant chemoradiotherapy in rectal c | Radiation Oncology | Articles preview

Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden
https://ro-journal.biomedcentral.com/articles/10.1186/s13014-021-01853-y

Pathological complete response (pathCR) in rectal cancer is beneficial, as up to 75% of patients do not experience regrowth of the primary tumour, but it is poorly understood. We hypothesised that the changes ...